Cumberland Pharmaceuticals CPIX Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 82.9%-2.1pp | 85%+0.5pp | 84.5%+0.5pp | 84%-0.3pp | 84.3%+1.7pp | |
| Operating margin | -17.2%-10.9pp | -6.3%+1.6pp | -7.9%-0.8pp | -7.1%+0.9pp | -8%+9.0pp | |
| Net margin | -17.6%-11.2pp | -6.4%+1.7pp | -8.1%-1.1pp | -7%+1.0pp | -8%+9.1pp | |
| EBITDA margin | -6.7%-9.8pp | 3%-0.2pp | 3.2%-0.8pp | 4%+0.3pp | 3.7%+7.7pp | |
| Returns | ||||||
| Return on equity | -29.4%-17.5pp | -11.9%+1.2pp | -13.1%-2.3pp | -10.8%+0.9pp | -11.7%+13.0pp | |
| Return on assets | -10.5%-6.8pp | -3.7%+0.9pp | -4.7%-0.7pp | -4%+0.3pp | -4.3%+3.9pp | |
| Return on invested capital | -42.2%-25.6pp | -16.6%+6.2pp | -22.8%-3.8pp | -19%+0.7pp | -19.7%+20.3pp | |
| Efficiency | ||||||
| Asset turnover | 0.6×0.0× | 0.6×0.0× | 0.6×0.0× | 0.6×0.0× | 0.5×+0.1× | |
| Inventory turnover | 0.7×+0.1× | 0.7×0.0× | 0.6×0.0× | 0.6×+0.1× | 0.6×0.0× | |
| Liquidity | ||||||
| Current ratio | 1×-0.1× | 1×-0.2× | 1.2×-0.1× | 1.3×+0.1× | 1.2×+0.1× | |
| Quick ratio | 0.7×-0.1× | 0.8×-0.1× | 0.9×-0.1× | 0.9×0.0× | 0.9×+0.1× | |
| Cash ratio | 0.3×0.0× | 0.3×-0.3× | 0.6×0.0× | 0.7×+0.1× | 0.6×0.0× | |
| Leverage | ||||||
| Debt-to-equity | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | 0.2×-0.3× | |
| Debt-to-assets | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×-0.1× | |
| Interest coverage | -17.3×-11.6× | -5.6×-0.2× | -5.4×-0.7× | -4.7×+0.3× | -5×+5.6× | |
| Per Share | ||||||
| Book value per share | $1.45-13.6% | $1.67-4.1% | $1.75-6.7% | $1.87-0.4% | $1.88+15.5% | |
| Valuation | ||||||
| Market capitalization | $97.09M+138% | $59.53M+27.5% | $46.68M-5.5% | $49.37M-16.4% | $59.09M+77.5% | |
| Enterprise value | $90.91M+207% | $53.02M+45.4% | $36.48M-5.0% | $38.38M-21.9% | $49.18M+91.3% | |
| Price / sales | 2.3×+1.3× | 1.3×+0.2× | 1.1×0.0× | 1.2×-0.3× | 1.4×+0.6× | |
| Price / book | 4.4×+3.0× | 2.4×+0.6× | 1.8×0.0× | 1.8×-0.3× | 2.1×+0.6× | |
| EV / sales | 2.1×+1.4× | 1.2×+0.3× | 0.9×0.0× | 0.9×-0.3× | 1.2×+0.5× | |
| Earnings yield | -7.7%-0.4pp | -4.8%+2.4pp | -7.1%-1.2pp | -5.9%-0.4pp | -5.5%+13.9pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Cumberland Pharmaceuticals's profit margins?
- Cumberland Pharmaceuticals (CPIX) runs a 82.9% gross margin and a -17.2% operating margin, with a -17.6% net margin.
- Where do Cumberland Pharmaceuticals's ratios come from?
- Every ratio is computed from Cumberland Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
